Idorsia Ltd
SIX:IDIA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Idorsia Ltd
Depreciation & Amortization
Idorsia Ltd
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Idorsia Ltd
SIX:IDIA
|
Depreciation & Amortization
CHf17.4m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Depreciation & Amortization
$705k
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Depreciation & Amortization
$19.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
16%
|
CAGR 10-Years
69%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Depreciation & Amortization
CHf1.8m
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-3%
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Depreciation & Amortization
CHf3.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Depreciation & Amortization
CHf1.9m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Idorsia Ltd
Glance View
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
See Also
What is Idorsia Ltd's Depreciation & Amortization?
Depreciation & Amortization
17.4m
CHF
Based on the financial report for Dec 31, 2025, Idorsia Ltd's Depreciation & Amortization amounts to 17.4m CHF.
What is Idorsia Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-2%
Over the last year, the Depreciation & Amortization growth was -2%. The average annual Depreciation & Amortization growth rates for Idorsia Ltd have been -4% over the past three years , -2% over the past five years .
